Dr. Pengfei Wang, Chief Scientific Officer of Adjuvax LLC, is a professor of Chemistry at UAB and a Senior Scientist of UAB’s Institute of Immunology. He has 15+ years of experience in molecular design, chemical synthesis, and immunological evaluation of saponin adjuvants. His structure-activity-relationship studies of 50+ synthetic and semisynthetic saponin adjuvants have led to the discovery of the VSA adjuvants.
Dr. Sue Michalek, Chief Technology Officer of Adjuvax LLC, is an emeritus professor of Microbiology at UAB, with expertise in mucosal vaccine development and the immunologic mechanisms involved in microbial-host interactions. She has 30+ years of experience in the development of vaccines against a variety of viral and microbial pathogens, including whole cell and subunit vaccines and a variety of antigen delivery systems and adjuvants.
Dr. Victoria Kim is the Vice President of R&D at Adjuvax LLC, where she leads the development and optimization of novel vaccine adjuvant formulations. She holds a Ph.D. in Organic Chemistry from UAB and specializes in vaccine adjuvant development and glycoconjugate vaccine synthesis.
Rebekah Beyea, Scientist and Business Development Manager at Adjuvax LLC, earned her B.S. in immunology and neuroscience with a minor in chemistry as well as her M.S. in multidisciplinary biomedical sciences with a concentration in immunology from UAB.
At Adjuvax, we are dedicated to developing potent, cost-effective, structurally defined, and highly accessible saponin adjuvants with diverse activity profiles tailored to various vaccine applications.
Stay Connected: